Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 63

1.

The many roles of histone deacetylases in development and physiology: implications for disease and therapy.

Haberland M, Montgomery RL, Olson EN.

Nat Rev Genet. 2009 Jan;10(1):32-42. doi: 10.1038/nrg2485. Review.

PMID:
19065135
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics.

Gallinari P, Di Marco S, Jones P, Pallaoro M, Steink├╝hler C.

Cell Res. 2007 Mar;17(3):195-211. Review.

PMID:
17325692
[PubMed - indexed for MEDLINE]
Free Article
3.

Histone deacetylases: target enzymes for cancer therapy.

Mottet D, Castronovo V.

Clin Exp Metastasis. 2008;25(2):183-9. Epub 2007 Dec 5. Review.

PMID:
18058245
[PubMed - indexed for MEDLINE]
4.

Protein deacetylases: enzymes with functional diversity as novel therapeutic targets.

Yoshida M, Shimazu T, Matsuyama A.

Prog Cell Cycle Res. 2003;5:269-78. Review.

PMID:
14593721
[PubMed - indexed for MEDLINE]
5.

The role of histone deacetylases (HDACs) in human cancer.

Ropero S, Esteller M.

Mol Oncol. 2007 Jun;1(1):19-25. doi: 10.1016/j.molonc.2007.01.001. Epub 2007 Mar 7. Review.

PMID:
19383284
[PubMed - indexed for MEDLINE]
Free Article
6.

Histone deacetylases in kidney development: implications for disease and therapy.

Chen S, El-Dahr SS.

Pediatr Nephrol. 2013 May;28(5):689-98. doi: 10.1007/s00467-012-2223-8. Epub 2012 Jun 22. Review.

PMID:
22722820
[PubMed - indexed for MEDLINE]
7.

Histone deacetylase inhibitors: a novel class of therapeutic agents in diabetic nephropathy.

Lee HB, Noh H, Seo JY, Yu MR, Ha H.

Kidney Int Suppl. 2007 Aug;(106):S61-6. Review.

PMID:
17653213
[PubMed - indexed for MEDLINE]
Free Article
8.

From discovery to the coming generation of histone deacetylase inhibitors.

Yoshida M, Matsuyama A, Komatsu Y, Nishino N.

Curr Med Chem. 2003 Nov;10(22):2351-8. Review.

PMID:
14529478
[PubMed - indexed for MEDLINE]
9.

Histone deacetylases and cancer: causes and therapies.

Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK.

Nat Rev Cancer. 2001 Dec;1(3):194-202. Review.

PMID:
11902574
[PubMed - indexed for MEDLINE]
10.

Histone tail modifications and noncanonical functions of histones: perspectives in cancer epigenetics.

Hadnagy A, Beaulieu R, Balicki D.

Mol Cancer Ther. 2008 Apr;7(4):740-8. doi: 10.1158/1535-7163.MCT-07-2284. Review.

PMID:
18413789
[PubMed - indexed for MEDLINE]
Free Article
11.

Focus on acetylation: the role of histone deacetylase inhibitors in cancer therapy and beyond.

Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG.

Expert Opin Investig Drugs. 2007 May;16(5):569-71. Review.

PMID:
17461732
[PubMed - indexed for MEDLINE]
12.

Histone deacetylases and cancer.

Barneda-Zahonero B, Parra M.

Mol Oncol. 2012 Dec;6(6):579-89. doi: 10.1016/j.molonc.2012.07.003. Epub 2012 Aug 27. Review.

PMID:
22963873
[PubMed - indexed for MEDLINE]
Free Article
13.

HDAC inhibitors for the treatment of cancer.

Secrist JP, Zhou X, Richon VM.

Curr Opin Investig Drugs. 2003 Dec;4(12):1422-7. Review.

PMID:
14763127
[PubMed - indexed for MEDLINE]
14.

Isoform-selective histone deacetylase inhibitors.

Itoh Y, Suzuki T, Miyata N.

Curr Pharm Des. 2008;14(6):529-44. Review.

PMID:
18336298
[PubMed - indexed for MEDLINE]
15.

Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis.

Shankar S, Srivastava RK.

Adv Exp Med Biol. 2008;615:261-98. doi: 10.1007/978-1-4020-6554-5_13. Review.

PMID:
18437899
[PubMed - indexed for MEDLINE]
16.

Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application.

Santini V, Gozzini A, Ferrari G.

Curr Drug Metab. 2007 May;8(4):383-93. Review.

PMID:
17504226
[PubMed - indexed for MEDLINE]
17.

Histone deacetylases and their functions in plants.

Ma X, Lv S, Zhang C, Yang C.

Plant Cell Rep. 2013 Apr;32(4):465-78. doi: 10.1007/s00299-013-1393-6. Epub 2013 Feb 14. Review.

PMID:
23408190
[PubMed - indexed for MEDLINE]
18.

Histone deacetylases: unique players in shaping the epigenetic histone code.

Thiagalingam S, Cheng KH, Lee HJ, Mineva N, Thiagalingam A, Ponte JF.

Ann N Y Acad Sci. 2003 Mar;983:84-100. Review.

PMID:
12724214
[PubMed - indexed for MEDLINE]
19.

Development of histone deacetylase inhibitors for cancer treatment.

Marchion D, M├╝nster P.

Expert Rev Anticancer Ther. 2007 Apr;7(4):583-98. Review.

PMID:
17428177
[PubMed - indexed for MEDLINE]
20.

Histone deacetylases as therapeutic targets in hematologic malignancies.

Melnick A, Licht JD.

Curr Opin Hematol. 2002 Jul;9(4):322-32. Review.

PMID:
12042707
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk